CNBX Swaps Auditor for India-Based Firm as Going-Concern Doubts Loom
Summary
CNBX Pharmaceuticals replaced its independent auditor with an India-based firm, effective September 28, 2026. The switch comes amid going-concern warnings and critically low cash.
Key Events · Corporate Governance and Compliance · CNBX
-
Auditor Dismissed
The board dismissed Elkana Amitai CPA as the independent registered public accounting firm, effective September 28, 2026.
-
New Auditor Engaged
Vilki & Co., based in Gujarat, India, was engaged the same day for the fiscal year ended August 31, 2026.
-
No Disagreements Reported
The company states there were no disagreements or reportable events with the former auditor during fiscal 2025 and 2026.
-
Going-Concern Warnings
The former auditor's reports for fiscal 2024 and 2025 included explanatory paragraphs citing substantial doubt about the company's ability to continue as a going concern.
Analysis · CNBX · Life Sciences
Effective September 28, 2026, CNBX Pharmaceuticals dismissed its auditor, Elkana Amitai CPA, and brought in Vilki & Co., a firm based in Gujarat, India. The prior auditor's reports for fiscal 2024 and 2025 had flagged going-concern warnings, and the latest 10-Q revealed critically low cash and mounting losses. Replacing the auditor with a small, overseas firm while the company's viability is in question raises a governance red flag that merits close attention.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.9% of the 1030 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNBX was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $160.6K. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.